Form 4: Disc Medicine CEO Exercises Options and Sells Shares Under 10b5-1 Plan

Disc Medicine's CEO, John D. Quisel, exercised stock options and sold shares on December 16, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• John D. Quisel, CEO of Disc Medicine, executed transactions involving the company's stock on December 16, 2024.
• These transactions included the exercise of stock options to acquire 12,791 shares at a price of $1.01 per share.
• Following the option exercise, Mr. Quisel sold a total of 12,791 shares in multiple transactions at weighted average prices ranging from $64.6586 to $67.198 per share.
• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on July 2, 2024.
• After these transactions, Mr. Quisel directly owns 72,065 shares of Disc Medicine common stock and 225,420 stock options.

Sentiment

Score: 5

Explanation: The document reflects routine insider transactions under a pre-arranged plan, which is neither positive nor negative for the company's outlook.

Industry Context

This is a routine filing related to insider transactions, which are common in publicly traded companies. The use of a 10b5-1 plan indicates that the transactions were pre-planned and not based on any material non-public information.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a common practice among executives at publicly traded companies to avoid accusations of insider trading.
• The reported transactions are typical for executives who receive stock options as part of their compensation.
• The sale prices are within the range of the company's recent trading activity, suggesting no unusual market impact.

Stakeholder Impact

• The transactions have a minimal impact on shareholders as they are part of a pre-planned trading strategy.

Key Dates

Keywords

Disc Medicine, John D. Quisel, stock options, share sales, Rule 10b5-1, insider trading, executive compensation